"Análise Crítica do JNC 7"

  • Dra. Andréa Araújo Brandão
  • Dr. Paulo Roberto Dutra da Silva
  • Dra. Maria Eliane Campos Magalhães
  • Dr. Antonio Sergio Cordeiro da Rocha

Referências

1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003;289(19):2560-72.

2. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. Hypertension 2003;42:1206-52.

3. Mion Jr. D, Machado CA, Gomes MAM, et al. IV Diretrizes Brasileiras de Hipertensão Arterial. Arq Bras Cardiol 2004;82 (supl IV):1-22.

4. Guidelines Committee. 2003 European Society of Hypertension – European Society of Cardioloy Guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.

5. Vasan RS, Beiser A, Seshadri S, et al. Residual life-time risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002;287:1003-1010.

6. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age specific relevance of ususal blood presuure to vascular mortality. Lancet 2002;360:1903-913.

7. Wilson PWF, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47

8. Kannel WB. Epidemiologic Contributions to Preventive Cardiology and Challenges for the Twenty-First Century. In: Wong ND, Black HR, Gardin JM (eds). Preventive Cardiology. New York : Mc Graw-Hill;2000:3-20.

9. Kavey RW, Daniels SR,Lauer RM, et al. American Heart Association Guidelines for Primary Prevention of Atherosclerotic Cardiovascular Disease Beginning in Childhood. Circulation 2003;107:1562-566.

10. Antihypertensive and Lipid-lowering Treatment to prevent Heart Attack Trial (The ALLHAT Group). Major outcomes in high-risk hypertensive patients radomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002;288:2981-997.

11. Antihypertensive and Lipid-lowering Treatment to prevent Heart Attack Trial (The ALLHAT Group). Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlortalidone. JAMA 2000;283:1967-975.

12. Kaplan NM. Treatment of Hypertension: why, when, how far. In Kaplan NM ed. Clinical Hypertension 8thed. Philadelphia: Lippincott Williams & Wilkins; 2002:176-205.

13. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003:362:1527-35.

14. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13

15. EUROPA Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.

16. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998;339:1957-63

17. Murray CJL, Lauer JA, Hutubessy RCW, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular disease risk. Lancet 2003;361:717-25

Voltar